Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1563-1570 , December 2009

A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation

Received 8 May 2009 ,Accepted 2 August 2009.

References 

  1. Finke J, Bertz H, Schmoor C, et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol. 2000;111:303–313
  2. Hale G, Zhang M-J, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;32:4581–4590
  3. Novitzky N, Thomas V. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies. Biol Blood Marrow Transplant. 2007;13:107–115
  4. Hale G, Xia MQ, Tighe HP, et al. The Campath-1 antigen (CD52). Tissue Antigens. 1990;35:118–127
  5. Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy. 2001;3:137–143
  6. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807–812
  7. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH 1 H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  8. Khouri IF, Albitar M, Saliba RM, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 2004;33:833–837
  9. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36:1001–1008
  10. Grüllich C, Bertz H, Spyridonidis A, et al. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant. 2008;41:845–850
  11. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–1484
  12. Marks R, Potthoff K, Hahn J, et al. Reduced-toxicity conditioning with fludarabine, BCNU and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematological malignancies. Blood. 2008;112:415–425
  13. Finke J, Schmoor C, Lang H, et al. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease pro-phylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003;21:506–513
  14. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097
  15. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyelo-ablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  16. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GvHD grading. Bone Marrow Transplant. 1995;15:825–828
  17. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  18. Popat U, Carrum G, May R, et al. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005;35:1127–1132
  19. Van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738
  20. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  21. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724–1730
  22. Anasetti C, Howe C, Petersdorf EW, et al. Marrow transplants from HLA matched unrelated donors: an NMDP update and the Seattle experience. Bone Marrow Transplant. 1994;13:693–695
  23. Dodero A, Carraba M, Milani R, et al. Reduced-intensity conditioning low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol. 2005;33:920–927
  24. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  25. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865–3871
  26. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–1627
  27. Lim Z, Baker B, Zuckermann M, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect. 2007;54:83–86
  28. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant. 2005;36:797–802
  29. Morris E, Rebello P, Thomson K, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood. 2003;102:404–406
  30. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma. 2007;48:256–269
  31. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127
  32. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–9393

 Present address for Alexandros Spyridonidis: Patras University Medical, School Rion/Patras 26500 Greece.

 Present address for Carsten Grüllich: National Cancer Center Heidelberg, Deparetment of Translational Oncology, D-69120 Heidelberg, Germany.

 Financial disclosure: See Acknowledgments on page 1569.

PII: S1083-8791(09)00366-8

doi: 10.1016/j.bbmt.2009.08.002

Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1563-1570 , December 2009

Article Tools

* Image Usage & Resolution